TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← Back to TickerSpark
▌Trending·October 29, 2026

Glaukos Corporation (GKOS) jumps on record Q3 results

Glaukos Corporation (GKOS) jumps after reporting record third-quarter sales, raising 2026 guidance and unveiling a preliminary $1 billion 2027 sales target. The stronger growth outlook, margin expansion and analyst target hikes helped push the stock above its prior close and 52-week high in after-hours trading.

TrendingGKOS
By TickerSpark·October 29, 2026·5 min read
Glaukos Corporation (GKOS) jumps on record Q3 results
▌Key Takeaway
Glaukos Corporation (GKOS) jumped 15.7% in after-hours trading after reporting record third-quarter revenue, stronger margins and a raised 2026 outlook. Management also introduced a preliminary $1 billion 2027 sales target, signaling a much bigger long-term growth runway for investors. The move reflects a meaningful reset in the stock’s valuation, though regular-session trading will determine whether the breakout holds.

Glaukos Corporation (GKOS) Jumps After Strong Q3 Results

Glaukos Corporation (GKOS) jumps 15.75% in after-hours trading to $210 after its October 28 third-quarter report delivered record sales, higher 2026 guidance and a preliminary $1B 2027 sales target. The move lifts the stock above its prior $181.43 close and its $191.62 52-week high; because this is an extended-hours print, regular-session trading will confirm whether the gain holds.

Key Takeaways

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

GKOS traded at $210 after hours, up 15.75% from the prior close and above its $191.62 52-week high.
  • The primary catalyst was Q3 revenue of $211.03M, up 58% year over year and 24.99% above the $168.84M consensus estimate.
  • Glaukos raised 2026 net sales guidance to $775M-$785M and introduced preliminary 2027 guidance of $1B.
  • The stronger growth outlook supports a higher valuation, but the $10.70B market cap also makes execution important after such a sharp repricing.
  • What's Behind GKOS's 15.75% After-Hours Jump

    The clearest catalyst is Glaukos's October 28 third-quarter earnings announcement. , an increase of 58% from the same quarter last year.

    That result changed the near-term growth narrative in two important ways. First, revenue growth accelerated across key operating areas. U.S. glaucoma sales reached $118.6M, up 47% year over year, while corneal health sales reached $59.0M, up 154%. Second, Glaukos raised full-year 2026 sales guidance from $680M-$700M to $775M-$785M.

    The company also gave investors a preliminary 2027 sales target of $1B. For a medical-device business with a $10.70B market cap, that figure adds a longer runway to the story. It also explains why the stock jumped beyond its prior trading range instead of reacting to the quarter as a routine earnings beat.

    Analyst actions reinforced the repricing on October 29. Piper Sandler raised its price target to $240 from $195, Needham set a $251 target, Mizuho set $225, and Truist raised its target to $255. Those updates did not create the original catalyst, but they added institutional support after the results.

    Get AI research on any stock

    Instant reports, daily intelligence, and an AI analyst in your pocket.

    Get Started →

    How Glaukos's Q3 Financial Results Reset the Growth Case

    The quarter offered more than top-line growth. Glaukos reported an approximately 85% gross margin, compared with about 78% in the prior-year quarter. Reported net income reached $2.0M, while non-GAAP net income was $28.5M.

    That combination matters because higher sales and wider gross margins give the business more room to absorb research, sales and commercialization costs. The company also ended the quarter with $339.8M in cash and investments, up $50.5M from the second quarter. The balance sheet therefore adds financial flexibility as Glaukos expands its product portfolio.

    The earnings picture was also stronger than the headline loss history shown in the stock data. Zacks reported adjusted Q3 earnings of $0.47 per share against a consensus estimate for a $0.12 loss. However, the most durable part of the investment case is the combination of $211.03M in revenue, higher guidance and the $1B preliminary 2027 target.

    Valuation remains the balancing factor. A $10.70B market cap against 2026 sales guidance of $775M-$785M places a high value on continued growth. Therefore, the stock now needs strong execution across several quarters, not just one impressive report, to justify the new price level.

    Why Glaukos's Ophthalmology Platform Supports the Premium

    Glaukos has built a broader ophthalmology platform rather than relying on one product. The company pioneered Micro-Invasive Glaucoma Surgery and commercially launched its first MIGS device in 2012. Its portfolio now includes iStent products, iDose TR for glaucoma, Epioxa for corneal health and an emerging retinal disease program.

    The latest results show why that platform matters. Glaucoma generated record U.S. sales of $118.6M, while corneal health grew to $59.0M. Glaukos has identified iDose TR and Epioxa as two transformational growth drivers, giving investors separate product paths inside the same company.

    The October 8 agreement with RevOpsis Therapeutics adds another layer. Glaukos received an exclusive license to develop and commercialize RO-104, a tri-specific biologic for retinal diseases, along with access to the RevMod platform for up to four additional biologic candidates. That deal did not trigger the current move, but it expands the long-term addressable market beyond glaucoma and corneal disorders.

    This mix of established devices, newer drug-device therapies and pipeline assets helps explain the market's enthusiasm. Still, a strong competitive position does not remove execution risk. Physician adoption, product launches and clinical development must continue to support the $775M-$785M 2026 outlook and the $1B 2027 ambition.

    How Investors Can Approach GKOS After the Earnings Repricing

    The fundamental upgrade is real: Q3 sales rose 58%, gross margin expanded to about 85%, 2026 guidance increased, and management introduced a $1B 2027 sales target. Those facts support a higher valuation framework for GKOS than the one in place before October 28.

    At the same time, a 15.75% after-hours gain creates a poor setting for emotional buying. A disciplined approach is to use the $181.43 regular-session close and the $191.62 52-week high as reference levels, then judge whether regular-session trading establishes support above those levels. For existing holders, the same prices provide concrete markers for assessing whether the breakout has conviction.

    GKOS is gaining because investors received a specific earnings and guidance reset, not because of vague sector excitement. If the company converts its record sales, margin expansion and 2027 target into sustained results, the after-hours jump marks a meaningful shift in the growth story. Regular-session price action will determine whether the market accepts that new valuation.

    Read the full GKOS research report
    ▌Common Questions

    Frequently asked questions

    +Why is GKOS stock up today?
    GKOS is up because Glaukos reported record Q3 sales of $211.0 million, far above expectations, and raised its 2026 guidance. The company also introduced a preliminary $1 billion 2027 sales target, which strengthened the growth outlook.
    +Should I buy GKOS stock now?
    The earnings update is strong, but the stock has already moved sharply higher, so chasing it immediately carries risk. A more disciplined approach is to wait for regular-session confirmation and see whether the breakout holds above prior resistance levels.
    +Did Glaukos beat earnings expectations in Q3?
    Yes. Glaukos reported adjusted Q3 earnings of $0.47 per share versus a consensus estimate for a $0.12 loss. Revenue also came in well above expectations.
    +What is the biggest catalyst for GKOS right now?
    The biggest catalyst is the combination of record revenue, expanding gross margins and higher forward guidance. The preliminary 2027 sales target of $1 billion is especially important because it suggests the company sees a much larger long-term market opportunity.
    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌The Full Report

    Want the full picture on GKOS?

    The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.

    Read the GKOS report →Get Full Access →

    Not ready to subscribe? ·

    ▌The Full Report

    Get the full GKOS research report

    • Analyst-grade deep dive
    • Charts, valuation, grades
    • Buy/sell price targets
    Read the GKOS report →
    ▌For Active Investors

    Smarter research, on every ticker

    • Daily market intelligence
    • On-demand stock analysis
    • AI analyst chat
    Get Full Access →

    Cancel anytime

    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, free in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌More on GKOS

    More to read

    All articles
    Glaukos (GKOS): Growth Surge Meets Premium Valuation
    GKOS

    Glaukos (GKOS): Growth Surge Meets Premium Valuation

    Glaukos is scaling rapidly on iDose TR and Epioxa, with Q3 revenue up 58% and 2027 sales guidance topping $1.0B. The stock still screens as a Hold because premium valuation and ongoing losses leave limited margin for error.

    Oct 28·20 min
    Glaukos Corporation (GKOS) Jumps 18.5% on Q3 Beat
    GKOS

    Glaukos Corporation (GKOS) Jumps 18.5% on Q3 Beat

    Glaukos Corporation (GKOS) jumps after a strong third-quarter report featuring record sales, rapid corneal-health growth, positive net income, and higher 2026 guidance. The move reflects renewed investor confidence in the company’s ophthalmology platform, though the stock now trades near the top of analyst expectations.

    Oct 28·5 min
    Michigan Consumer Sentiment Rebounds as Inflation Expectations Fall

    Michigan Consumer Sentiment Rebounds as Inflation Expectations Fall

    US consumer confidence improved in November, with the Michigan sentiment index rising to 51.5 and inflation expectations easing sharply. The rebound looks fragile, but the drop in year-ahead price expectations offers a more important signal for markets and Federal Reserve policy.

    Nov 20·5 min